Literature DB >> 17630545

Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe.

Joelle M Brown1, Anna Wald, Alan Hubbard, Kittipong Rungruengthanakit, Tsungai Chipato, Sungwal Rugpao, Francis Mmiro, David D Celentano, Robert S Salata, Charles S Morrison, Barbra A Richardson, Nancy S Padian.   

Abstract

BACKGROUND: An association has been demonstrated between herpes simplex type 2 (HSV-2) and HIV infection among men, but prospective studies in women have yielded mixed results.
OBJECTIVE: To estimate the effects of prevalent and incident HSV-2 infection on subsequent HIV acquisition among women in two African countries.
DESIGN: Prospective cohort study.
METHODS: HSV-2 and HIV serostatus were evaluated at enrollment and quarterly for 15-24 months among 4531 sexually active, HIV-uninfected women aged 18-35 years from Uganda and Zimbabwe. The association between prior HSV-2 infection and HIV acquisition was estimated using a marginal structural discrete survival model, adjusted for covariates.
RESULTS: HSV-2 seroprevalence at enrollment was 52% in Uganda and 53% in Zimbabwe; seroincidence during follow-up was 9.6 and 8.8/100 person-years in Uganda and Zimbabwe, respectively. In Uganda, the hazard ratio (HR) for HIV was 2.8 [95% confidence interval (CI), 1.5-5.3] among women with seroprevalent HSV-2 and 4.6 (95% CI, 1.6-13.1) among women with seroincident HSV-2, adjusted for confounding. In Zimbabwe, the HR for HIV was 4.4 (95% CI, 2.7-7.2) among women with seroprevalent HSV-2, and 8.6 (95% CI, 4.3-17.1) among women with seroincident HSV-2, adjusted for confounding. The population attributable risk percent for HIV due to prevalent and incident HSV-2 infection was 42% in Uganda and 65% in Zimbabwe.
CONCLUSIONS: HSV-2 plays an important role in the acquisition of HIV among women. Efforts to implement known HSV-2 control measures, as well as identify additional measures to control HSV-2, are urgently needed to curb the spread of HIV.

Entities:  

Mesh:

Year:  2007        PMID: 17630545     DOI: 10.1097/QAD.0b013e3282004929

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  44 in total

Review 1.  Immune modulation during latent herpesvirus infection.

Authors:  Douglas W White; R Suzanne Beard; Erik S Barton
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  Evaluation of the HerpeSelect Express rapid test in the detection of herpes simplex virus type 2 antibodies in patients with genital ulcer disease.

Authors:  Hani Al-Shobaili; Khaled M Hassanein; Marwa Salah Mostafa; Ali Saleh Al Duways
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

3.  Herpes simplex virus type 2 associated with HIV infection among New York heterosexuals living in high-risk areas.

Authors:  H Hagan; S M Jenness; T Wendel; C R Murrill; A Neaigus; C Gelpi-Acosta
Journal:  Int J STD AIDS       Date:  2010-08       Impact factor: 1.359

4.  Use of injectable hormonal contraception and HSV-2 acquisition in a cohort of female sex workers in Vancouver, Canada.

Authors:  M Eugenia Socías; Putu Duff; Jean Shoveller; Julio S G Montaner; Paul Nguyen; Gina Ogilvie; Kate Shannon
Journal:  Sex Transm Infect       Date:  2016-11-07       Impact factor: 3.519

5.  New insights on interactions between HIV-1 and HSV-2.

Authors:  Sinéad Delany-Moretlwe; Jairam R Lingappa; Connie Celum
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

6.  The impact of brief messages on HSV-2 screening uptake among female defendants in a court setting: a randomized controlled trial utilizing prospect theory.

Authors:  Alexis M Roth; Barbara Van Der Pol; J Dennis Fortenberry; Brian Dodge; Michael Reece; David Certo; Gregory D Zimet
Journal:  J Health Commun       Date:  2014-12-12

7.  Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs.

Authors:  Yo Hoshino; Lesley Pesnicak; Kennichi C Dowdell; Juan Lacayo; Timothy Dudek; David M Knipe; Stephen E Straus; Jeffrey I Cohen
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

8.  Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2.

Authors:  Jérôme LeGoff; Philippe Mayaud; Gérard Gresenguet; Helen A Weiss; Khonde Nzambi; Eric Frost; Jacques Pepin; Laurent Belec
Journal:  J Clin Microbiol       Date:  2008-04-02       Impact factor: 5.948

9.  Structure activity relationship of dendrimer microbicides with dual action antiviral activity.

Authors:  David Tyssen; Scott A Henderson; Adam Johnson; Jasminka Sterjovski; Katie Moore; Jennifer La; Mark Zanin; Secondo Sonza; Peter Karellas; Michael P Giannis; Guy Krippner; Steve Wesselingh; Tom McCarthy; Paul R Gorry; Paul A Ramsland; Richard Cone; Jeremy R A Paull; Gareth R Lewis; Gilda Tachedjian
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

10.  The prevalence, incidence and risk factors of herpes simplex virus type 2 infection among pregnant Zimbabwean women followed up nine months after childbirth.

Authors:  Marshall W Munjoma; Edith N Kurewa; Munyaradzi P Mapingure; Grace V Mashavave; Mike Z Chirenje; Simbarashe Rusakaniko; Akhtar Hussain; Babill Stray-Pedersen
Journal:  BMC Womens Health       Date:  2010-01-12       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.